Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.

Browse

Order by:     Display #  

<< Start < Prev 1 2 Next > End >>


Stakeholder Opinions: Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only


$3 800.00    Product Details...


Stakeholder Opinions: Hepatocellular Carcinoma

The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in


$3 800.00    Product Details...


Stakeholder Opinions: Female Sexual Dysfunction

Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the cl


$3 800.00    Product Details...


Stakeholder Opinions: Esophageal Cancer

Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients


$3 800.00    Product Details...


Non-hormonal Treatments for Menopausal Symptoms

The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highl


$3 800.00    Product Details...


Stakeholder Opinions: Systemic Lupus Erythematosus

Key issues in Systemic Lupus Erythematosus (SLE) are discussed, including opportunities and threats in the market and analysis of novel therapies in the developmental pipeline.


$3 800.00    Product Details...


Stakeholder Opinions: Primary Brain Cancer

Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2


$3 800.00    Product Details...


Stakeholder Opinions: Diabetic Renal Disease
In-depth analysis on the latest challenges, trends and developments in diagnosis, pharmacological and non- pharmacological treatment of Diabetic Renal Disease.

$3 800.00    Product Details...


Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency

Investigation of the state of alpha-1 antitrypsin deficiency market, discussion of the regional variability of predisposing genotypes, disease description, pipeline details and factors hindering the development of new treatments.


$3 800.00    Product Details...


Stakeholder Opinions: Bone Metastases

Key issues in bone metastases, including mechanisms of normal and altered bone metabolism, epidemiology data, current treatment options, unmet needs, analysis of pipeline drugs in direct development for bone metastases and key stakeholder opinions.


$3 800.00    Product Details...


Stakeholder Opinions: Multiple Myeloma

The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; C


$3 800.00    Product Details...


Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesot

SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is


$3 800.00    Product Details...


Stakeholder Opinions: Sepsis

Key issues surrounding product development for sepsis, severe sepsis and septic shock. Analysis of the major clinical and commercial defining the four key areas of optimised individual treatment: predisposition, infection, response and organ failure.

$3 800.00    Product Details...


Stakeholder Opinion: Atopic Dermatitis

Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader inte


$3 800.00    Product Details...


Stakeholder Opinions: Percutaneous Coronary Intervention

While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: "in-stent thrombosis". Opinion leaders are divided over the grav


$3 800.00    Product Details...


Stakeholder Opinions: Non-Hodgkins Lymphoma

Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in


$3 800.00    Product Details...


Stakeholder Opinions: Fibromyalgia

Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical


$3 800.00    Product Details...


Stakeholder Opinions: Biologics in Infectious Diseases

Explores key issues in the development of biologics for infectious diseases. It identifies promising targets, highlights development difficulties and gives an overview of antibacterial, antiviral and antifungal pipeline projects.


$3 800.00    Product Details...


Stakeholder Opinions: Hepatitis C

Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited


$3 800.00    Product Details...


Stakeholder Opinions: Portable Inhaler Devices

An overview ofthe market for portable inhalers, looking at market shares,usefulness as tools for franchise protection and -expansion. Patient- and physician preferences are being analyzed as well as suitablility of molecules and inhaler types.


$3 800.00    Product Details...


Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted...

A meager 20% of metastatic RCC tumors respond to standard cytokine therapy, thus rendering 80% of advanced RCC patients without any effective treatment. Further, with up to 50% of stage one to three patients relapsing following nephrectomy and an incre


$3 800.00    Product Details...


Stakeholder Opinions: Sexually Transmitted Infections

The global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underreporting is likely to mask the real incidence. Most STIs can lead to severe sequelae, including infer


$3 800.00    Product Details...


Stakeholder Opinions: Idiopathic Pulmonary Fibrosis - A New Hope

Idiopathic pulmonary fibrosis is a devastating, relentlessly progressive and lethal disease for which current therapy is minimally effective. However, several promising anti-fibrotic agents, such as Enbrel (etanercept), are now in clinical trials, whic


$3 800.00    Product Details...


Stakeholder Opinions: Chronic Leukemias - Curative Intent

Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovat


$3 800.00    Product Details...


Stakeholder Opinions: Head & Neck Cancer - Innovatives to Change

The incidence of head and neck cancers is increasing. Surgery and radiation are employed with curative intent for early stage lesions. Chemotherapy concurrent with radiation and surgery is the treatment of choice for unresectable disease. The market is


$3 800.00    Product Details...


Stakeholder Opinions:Primary Brain Cancer-Temozolomide Turn Head

The incidence of glioblastoma is increasing. Schering-Plough`s temozolomide has gained approval as first line therapy for glioblastoma and has provided some survival benefit. However, median survival is still a modest fifteen months. Thus, the glioblas


$3 800.00    Product Details...


Stakeholder Opinions: Minimally Invasive Spinal Surgery...

As in other areas of surgery, surgeons are looking to reduce the invasive nature of spinal surgery, in an attempt to improve patient outcomes. The potential benefits of minimally invasive spinal surgery such as microdiscectomy and mini spinal fusion in


$3 800.00    Product Details...


Stakeholder Opinions: Brain Metastases

The incidence of brain metastasis is escalating concurrent with improvements in systemic therapy increasing patient survival. There is no approved pharmacotherapy for these patients and current therapy is palliative. Median survival is four months. Thu


$3 800.00    Product Details...


Stakeholder Opinions: Migraine - Lots of Experience...

Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow phar


$3 800.00    Product Details...